The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial
Abstract
Rationale: Nintedanib and pirfenidone slow the progression of idiopathic pulmonary fibrosis (IPF), but the disease continues to progress. More data are needed on the safety and efficacy of combination therapy with nintedanib and add-on pirfenidone. Objectives: To investigate safety, tolerability, and pharmacokinetic and exploratory efficacy endpoints in patients treated with nintedanib and add-on pirfenidone versus nintedanib alone. Methods: Patients with IPF and FVC greater than or equal to 50% predicted at screening who completed a 4- to 5-week run-in with nintedanib 150 mg twice daily without dose reduction or treatment interruption were randomized to receive nintedanib 150 mg twice daily with add-on pirfenidone (titrated to 801 mg three times daily) or nintedanib 150 mg twice daily alone in an open-label manner for 12 weeks. The primary endpoint was the percentage of patients with on-treatment gastrointestinal adverse events from baseline to Week 12. Analyses were descriptive and exploratory. Measurements and Main Results: On-treatment gastrointestinal adverse events were reported in 37 of 53 patients (69.8%) treated with nintedanib with add-on pirfenidone and 27 of 51 patients (52.9%) treated with nintedanib alone. Predose plasma trough concentrations of nintedanib were similar when it was administered alone or with add-on pirfenidone. Mean (SE) changes from baseline in FVC at Week 12 were −13.3 (17.4) ml and −40.9 (31.4) ml in patients treated with nintedanib with add-on pirfenidone (n = 48) and nintedanib alone (n = 44), respectively. Conclusions: Nintedanib with add-on pirfenidone had a manageable safety and tolerability profile in patients with IPF, in line with the adverse event profiles of each drug. These data support further research into combination regimens in the treatment of IPF. Clinical trial registered with www.clinicaltrials.gov (NCT02579603).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lee and colleagues did a meta-analysis on four clinical trials that included 191 IPF patients treated with a combination of pirfenidone and nintedanib [85]. Gastrointestinal symptoms were the most common adverse event reported. About 29% of the combination treated patients stopped the trials with a high serious and any adverse event rates noted.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [85]
In the citing paper
“Background nintedanib was not allowed because previous small clinical trials assessing the combination of nintedanib and pirfenidone have shown high rates of adverse events and discontinuation that could have compromised study integrity.17,18”
From Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial (2026) · cites this paper as [17]
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627 · cited 3×
“Some of these results were presented at the 2017 European Respiratory Society (ERS) International Congress in abstract form.”
MethodRaghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005 · cited 1×
“Nintedanib and pirfenidone have pleiotropic effects and are thought to target different aspects of the fibrotic cascade (9, 10), suggesting that therapy with both drugs”
BackgroundSelf-citationNew cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis
Fernandez, I. E., & Eickelberg, O. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61144-1 · Cited by 437 · cited 1×
“Activated alveolar epithelial cells release fibrogenic growth factors that promote the migration, activation, and differentiation of fibroblasts and myofibroblasts, resulting in excessive deposition of extracellular matrix and the destruction of the lung architecture (2).”
BackgroundConte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., & Vancheri, C. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.014 · Cited by 368 · cited 1×
“Nintedanib and pirfenidone have pleiotropic effects and are thought to target different aspects of the fibrotic cascade (9, 10), suggesting that therapy with both drugs”
BackgroundSelf-citationSafety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
Ogura, T., Taniguchi, H., Azuma, A., Inoue, Y., Kondoh, Y., Hasegawa, Y., Bando, M., Abe, S., Mochizuki, Y., Chida, K., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00198013 · Cited by 215 · cited 5×
“These were reported more commonly in the 13 patients who received nintedanib 150 mg twice daily on top of pirfenidone background therapy (in 4 and 5 patients, respectively) compared with the 11 patients who received nintedanib 150 mg twice daily only (in 1 and no patients, respectively) (11).”
BackgroundMethodResultInfluentialSafety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Corte, T., Bonella, F., Crestani, B., Demedts, M. G., Richeldi, L., Coeck, C., Pelling, K., Quaresma, M., & Lasky, J. A. (2015) · Respiratory Research · doi:10.1186/s12931-015-0276-5 · Cited by 175 · cited 1×
“occurred within the first 3 months (14, 15).”
BackgroundSelf-citation
Research works printed but not linked: 3
- Taniguchi, 2016, Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF [abstract], Eur Respir J, 48, PA2089
- Mason, 2017, Time-to-event analysis of common adverse events with pirfenidone in patients with IPF: a pooled analysis of three phase III clinical trials [abstract], Am J Respir Crit Care Med, 195, A6798
- Flaherty, 2017, Safety of the combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from an interim analysis after 12 weeks [astract], Am J Respir Crit Care Med, 195, A5398
Cited by
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Idiopathic Pulmonary Fibrosis (IPF): An Overview
Barratt, S., Creamer, A., Hayton, C., & Chaudhuri, N. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080201 · Cited by 382
“Recent studies have assessed combination therapy with both antifibrotics and have reported adequate tolerability with promising secondary efficacy data [143,144].”
BackgroundIdiopathic Pulmonary Fibrosis: An Update on Pathogenesis
Mei, Q., Liu, Z., Zuo, H., Yang, Z., & Qu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797292 · Cited by 360
The therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
Self-citation
Metadata
- Authors
- Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C. J., Valeyre, D., Grutters, J. C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., & Wuyts, W. A.
- Affiliations
- University of Catania (IT)
- Heidelberg University (DE)
- Università Cattolica del Sacro Cuore (IT)
- University of British Columbia (CA)
- Assistance Publique – Hôpitaux de Paris (FR)
- University Medical Center Utrecht (NL)
- Boehringer Ingelheim (Germany) (DE)
- Universitair Ziekenhuis Leuven (BE)
- Corresponding author
- Vancheri, Carlo
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-01
- Volume
- 197
- Issue
- 3
- Pages
- 356-363
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2753035500
- Cited by
- 305
- References
- 11
- Citations by year
- 2026: 26 · 2025: 29 · 2024: 38 · 2023: 37 · 2022: 34 · 2021: 36 · 2020: 32 · 2019: 43 · 2018: 27
- FWCI
- 23.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, nintedanib, pirfenidone, combination therapy, adjunctive therapy, gastrointestinal adverse effects, safety and tolerability, pharmacokinetics, forced vital capacity, antifibrotic agents
- MeSH terms
- Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Indoles, Male, Middle Aged, Pyridones, Severity of Illness Index, Survival Rate, Treatment Outcome, Disease Progression, Risk Assessment, Idiopathic Pulmonary Fibrosis, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. https://app.cochat.ai/papers/10.1164/rccm.201706-1301oc
- The paper
- Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C. J., Valeyre, D., Grutters, J. C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., & Wuyts, W. A. (2018). Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201706-1301oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.